Clinical usefulness of E4-phytohemagglutinin reactive C4-binding protein relative front value in serum for distinguishing between ovarian clear cell adenocarcinoma and endometrioma
Clinica Chimica Acta · 2025
DOI: 10.1016/j.cca.2025.120219 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinica Chimica Acta, 2025. Verfasst von Kayoko Shimizu und 6 weiteren Autor:innen. Beteiligte Einrichtung: Research Institute of Clinical Diagnostics, Fujifilm Wako Pure Chemical Corporation, Osaka, Japan. Electronic address: kayoko.kidowaki@fujifilm.com. Hauptthemen laut MEDLINE: Endometriosis, Ovarian Neoplasms, Adenocarcinoma, Clear Cell, Complement C4b-Binding Protein. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
BACKGROUND AND AIMS: We identified a fully sialylated glycopeptide of the α-chain of Complement 4 binding protein (C4BP) in blood using Liquid chromatography/Mass spectrometry, which helps differentiate ovarian clear cell carcinoma (OCCC) from endometrioma (EM). We aimed to develop a blood measurement system to immunologically assess fully sialylated α-chain of C4BP, specifically E4-phytohemagglutinin-reactive C4BP (P-C4BP-Rf). MATERIALS AND METHODS: Ninety-seven serum samples were collected from healthy (HE) (n = 11), uterine fibroid (UF) patients (n = 15), EM patients (n = 32), and OCCC patients (n = 39). P-C4BP-Rf was measured using lectin affinity electrophoresis and antibody affinity blotting. CA125 and human epididymal protein 4 (HE4) levels were also measured and compared. We selected 22 EM and 24 OCCC with no significant differences in CA125 levels. Tissue factor pathway inhibitor 2 (TFPI2) and FS-C4BP were added to the analysis to distinguish OCCC from EM using five biomarkers. RESULTS: P-C4BP-Rf was significantly higher in OCCC than in HE, UF, and EM (P < 0.0001). AUC values were: CA125, 0.547; HE4, 0.850; TFPI2, 0.847; FS-C4BP, 0.715; and P-C4BP-Rf, 0.887. The combination of P-C4BP-Rf and HE4 yielded the highest AUC (0.960). CONCLUSION: P-C4BP-Rf is useful for distinguishing OCCC from EM and may be more accurate when combined with HE4.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Research Institute of Clinical Diagnostics, Fujifilm Wako Pure Chemical Corporation, Osaka, Japan. Electronic address: kayoko.kidowaki@fujifilm.com.
- Research Institute of Clinical Diagnostics, Fujifilm Wako Pure Chemical Corporation, Osaka, Japan. Electronic address: tomotaka.sakamoto@fujifilm.com.
- Research Institute of Clinical Diagnostics, Fujifilm Wako Pure Chemical Corporation, Osaka, Japan. Electronic address: toshinari.ohashi@fujifilm.com.
- Medical Solution Segment LSI Medience Corporation, Tokyo, Japan. Electronic address: tanabe.kazuhiro@mp.medience.co.jp.
- Department of Obstetrics and Gynecology, Tokai University School of Medicine, Kanagawa, Japan. Electronic address: hayashiio@tokai.ac.jp.
- Faculty of Medical Sciences, Shonan University of Medical Sciences, Kangawa, Japan; Department of Gynecology, Chigasaki Central Hospital, Kanagawa, Japan. Electronic address: ikedam@tokai.ac.jp.
Förderung
- Japan Agency for Medical Research and Development
Zitieren
APA
Shimizu, K., Sakamoto, T., Ohashi, T., Tanabe, K., Hayashi, I., Ikeda, M., & Mikami, M. (2025). Clinical usefulness of E4-phytohemagglutinin reactive C4-binding protein relative front value in serum for distinguishing between ovarian clear cell adenocarcinoma and endometrioma. Clinica Chimica Acta. https://doi.org/10.1016/j.cca.2025.120219
Vancouver
Shimizu K, Sakamoto T, Ohashi T, Tanabe K, Hayashi I, Ikeda M, et al. Clinical usefulness of E4-phytohemagglutinin reactive C4-binding protein relative front value in serum for distinguishing between ovarian clear cell adenocarcinoma and endometrioma. Clinica Chimica Acta. 2025. doi:10.1016/j.cca.2025.120219
BibTeX
@article{Shimizu2025,
author = {Shimizu, Kayoko and Sakamoto, Tomotaka and Ohashi, Toshinari and Tanabe, Kazuhiro and Hayashi, Io and Ikeda, Masae and Mikami, Mikio},
title = {Clinical usefulness of E4-phytohemagglutinin reactive C4-binding protein relative front value in serum for distinguishing between ovarian clear cell adenocarcinoma and endometrioma},
journal = {Clinica Chimica Acta},
year = {2025},
doi = {10.1016/j.cca.2025.120219}
}
EUVIMED